NKGN (NKGen Biotech) Loans Receivable: $0.00 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is NKGen Biotech Loans Receivable?

NKGen Biotech NKGN -4.76% Loans Receivable is $0.00 Mil as of Mar. 2025.

NKGen Biotech's Loans Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.

NKGen Biotech Loans Receivable Historical Data

* Premium members only.

The historical data trend for NKGen Biotech's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech Loans Receivable Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Loans Receivable
0.00 0.00 0.00 0.00

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NKGen Biotech Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
NKGen Biotech (NKGN) has a Loans Receivable of $0.00 Mil as of Mar. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on NKGen Biotech and its competitors.
Is NKGen Biotech's Loans Receivable too high?
NKGen Biotech's current Loans Receivable is $0.00 Mil.
How does NKGen Biotech's Loans Receivable compare to CALC and CLGN?
NKGen Biotech's Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on NKGen Biotech and its competitors. NKGen Biotech's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NKGen Biotech stock overvalued right now?
NKGen Biotech (NKGN) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For NKGen Biotech (NKGN), the current Loans Receivable is $0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NKGen Biotech Business Description

Address 3001 Daimler Street, Santa Ana, CA, USA, 92705
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.